

## HYPOFIBRINOGENEMIA IN BLEEDING CARDIAC SURGERY: A PROBLEM IN DISGUISE

*Dr. Worasak Keeyapaj, Stanford University*

Excessive post-operative hemorrhage in cardiac surgery is known to result in substantial increases in post-operative complications such as need for re-exploration, prolonged ICU stay, ventilation for >24 hours, need for any kind of blood products and associated risks, and increased mortality.<sup>1</sup> Several

professional societies have published protocols for assessing coagulopathy and optimizing blood component replacement aiming to stop bleeding as quickly as possible. A 1:1:1 transfusion ratio of red cells to platelets to plasma shows a benefit for massive hemorrhage treatment in cardiovascular surgery.<sup>2</sup>

A targeted (goal directed) transfusion algorithm promotes individual component therapy with concentrated clotting factors instead of a fixed ratio transfusion in cardiac surgery. Fibrinogen, the precursor for fibrin, a key protein in clot formation, is the first clotting factor to reach critically low levels during hemorrhage.<sup>3</sup>

>> continued on page 2

## WINNING WITH A NOVEL STATISTICAL ANALYSIS IN CT TRIALS: USE OF THE WIN RATIO

*Kevin W. Lobdell, Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC*

*Andrew D. Shaw, Cleveland Clinic, Cleveland, OH*

*Andre Lamy, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada*

RBT-1 is a novel preconditioning drug being developed to prevent postoperative complications in patients undergoing cardiothoracic surgery. It activates various antioxidant, anti-inflammatory, and iron-scavenging pathways and, when administered

>> continued on page 3

## POST-OPERATIVE ATRIAL FIBRILLATION: CLINICAL IMPLICATIONS, GUIDELINES, AND EMERGING EVIDENCE

*Marc W Gerdisch MD  
Loyola University Medical Center, Chicago, IL*

New-onset post-operative atrial fibrillation (POAF) occurs in 20-50% of patients after cardiac surgery. POAF usually develops within the index hospital stay and often extends it. Post-discharge POAF may be underdiagnosed. POAF is not a benign condition: it confers a 5- to 8-fold risk of AF recurrence<sup>1,2</sup> and has been associated with increased risks of stroke and mortality, as demonstrated by large meta-analyses.<sup>3,4</sup> POAF reveals atrial myopathy and atrial myocardial substrate vulnerable to fibrillation. The substrate for AF exists before the episode of POAF and of course,

persists as a durable risk. Thus, lessening the likelihood of POAF with temporary drug therapy or inflammation reduction may not confer substantial long-term protection.

The ESC/EACTS gave a 2020 Class I (Level of Evidence [LOE] A) recommendation for peri-operative amiodarone or beta-blockers for POAF prevention, whereas a 2a recommendation (LOE B) was given by ACC in 2023. However, these drugs may be underutilized in part due to side effects, including bradycardia, or real-world use compliance. Long-term

>> continued on page 4

## MORE INSIDE:

- *Introducing:  
The Virtual Training Center (VTC)*
- *Announcing:  
The 2024 ERAS® Cardiac Fellowship Awardee*
- *Upcoming Meetings*
- *ERAS Members & Sponsors*
- *Our Mission*

## ERAS PROGRAM IN THE SPOTLIGHT

### THE I HATE INFECTIONS TEAM (#IHIT)

*Mike Modrow PA-C  
WakeMed Health, Raleigh NC*

Enhanced recovery after heart surgery (ERAS®) must include infection prevention strategies.<sup>1</sup> WakeMed's cardiac surgery service line developed a robust, multidisciplinary infection prevention team to evaluate and act in all phases of perioperative care to achieve a cardiac surgery DSWI rate of zero. We call this team the *I Hate Infections Team*.<sup>2</sup>

Patient-related interventions consisted of pre-operative methicillin-resistant Staphylococcus

aureus identification, individualized perioperative antibiotics, antimicrobial dosing strategies, and maintenance of normothermia.

Operative-related interventions involved glycemic control, sternal adhesives, medications and hemostasis, rigid sternal fixation for high-risk patients, chlorhexidine gluconate dressings over invasive lines, and use of disposable health care equipment, where able, to prevent cross contamination.

>> continued on page 5

## HYPOFIBRINOGENEMIA IN BLEEDING CARDIAC SURGERY: A PROBLEM IN DISGUISE

Dr. Worasak Keeyapaj  
Stanford University

>> continued from page 1

Pre-operative fibrinogen levels in cardiac surgery are independently associated with post-operative blood loss and re-exploration.<sup>4</sup> Similarly, post-operative fibrinogen levels below 200 mg/dL are an independent risk factor for severe hemorrhage.<sup>5</sup>

Early identification and prompt treatment of hypofibrinogenemia by viscoelastic

whereas fibrinogen concentrate contains only fibrinogen.<sup>9,10</sup> Risk of infection transmission delaying treatment due to thawing time and high wastage due to its short shelf-life (4-6 hours) are limitations of cryoprecipitated AHF. The high cost and lack of other clotting factors are the drawbacks of fibrinogen concentrate. Factor XIII promotes the cross-linkage of fibrin monomer into fibrin polymer and strengthens the blood

reduced cryoprecipitated fibrinogen complex (Cerus®, Concord, CA) has been introduced as an alternative treatment option for hypofibrinogenemia. It can be stored in thawed-form, ready-to-transfuse, for up to 5 days and in addition to fibrinogen, contains other clotting factors such as vWF and factor XIII.<sup>13</sup> Early detection and prompt treatment of acquired hypofibrinogenemia in bleeding cardiac surgical patients with a concentrated source of fibrinogen may reduce adverse outcomes associated with hemorrhage.

### EARLY IDENTIFICATION AND PROMPT TREATMENT OF HYPOFIBRINOGENEMIA BY VISCOELASTIC TESTING OR LABORATORY TESTING IS ASSOCIATED WITH REDUCED BLOOD COMPONENT UTILIZATION AND IMPROVED MORTALITY RATES IN CARDIOVASCULAR SURGERY.

testing or laboratory testing is associated with reduced blood component utilization and improved mortality rates in cardiovascular surgery.<sup>6,7</sup> The common treatments for acquired hypofibrinogenemia are cryoprecipitated AHF and fibrinogen concentrate. Cryoprecipitated AHF<sup>8</sup> replenishes fibrinogen as well as von Willebrand factor (vWF), factor VIII and factor XIII,


clot. The result of FIBRES trial showed the efficacy of fibrinogen concentrate was non-inferior to cryoprecipitated AHF in bleeding cardiac surgical patients with hypofibrinogenemia.<sup>11</sup> However, the REPLACE trial showed fibrinogen concentrate administration in bleeding cardiac surgical patients was associated with increased allogenic blood transfusion.<sup>12</sup> Recently, pathogen

1. Christensen MC, Krapf S, Kempel A, von Heymann C. Costs of excessive postoperative hemorrhage in cardiac surgery. *The Journal of Thoracic and Cardiovascular Surgery* 2009;138(3):687-693. DOI: <https://doi.org/10.1016/j.jtcvs.2009.02.021>.

2. Delaney M, Stark PC, Suh M, et al. Massive Transfusion in Cardiac Surgery: The Impact of Blood Component Ratios on Clinical Outcomes and Survival. *Anesthesia and analgesia* 2017;124(6):1777-1782. (In eng). DOI: [10.1213/ane.0000000000001926](https://doi.org/10.1213/ane.0000000000001926).

3. Hagemo JS, Stanworth S, Juffermans NP, et al. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. *Critical*

>> continued on page 3



## HYPOFIBRINOGENEMIA IN BLEEDING CARDIAC SURGERY: A PROBLEM IN DISGUISE

*Dr. Worasak Keeyapaj, Stanford University*

>> continued from page 2

*care 2014;18(2):R52. (journal article). DOI: 10.1186/cc13798.*

4. Waldén K, Jeppsson A, Nasic S, Backlund E, Karlsson M. Low Preoperative Fibrinogen Plasma Concentration Is Associated With Excessive Bleeding After Cardiac Operations. *The Annals of Thoracic Surgery* 2014;97(4):1199-1206. DOI: 10.1016/j.athoracsur.2013.11.064.

5. Ranucci M, Pistuddi V, Baryshnikova E, Colella D, Bianchi P. Fibrinogen Levels After Cardiac Surgical Procedures: Association With Postoperative Bleeding, Trigger Values, and Target Values. *The Annals of Thoracic Surgery* 2016;102(1):78-85. DOI: 10.1016/j.athoracsur.2016.01.005.

6. Pearse BL, Smith I, Faulkner D, et al. Protocol guided bleeding management improves

cardiac surgery patient outcomes. *Vox Sang* 2015;109(3):267-79. (Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1111/vox.12279.

7. Hinton JV, Xing Z, Fletcher CM, et al. Association of perioperative cryoprecipitate transfusion and mortality after cardiac surgery. *The Annals of Thoracic Surgery* 2023. DOI: 10.1016/j.athoracsur.2023.02.054.

8. AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2021.

9. FIBRYGA®, Fibrinogen (Human) Lyophilized Powder for Reconstitution [package insert]. Paramus, NJ: Octapharma USA, Inc; December, 2020.

10. RIASTAP, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection. Kankakee, IL: CSL Behring LLC; July, 2021.

11. Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. *JAMA* 2019;1-11. (In eng). DOI: 10.1001/jama.2019.17312.

12. Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. *British journal of anaesthesia* 2016;117(1):41-51. (In eng). DOI: 10.1093/bja/aew169.

13. INTERCEPT Blood System for Cryoprecipitation [Package Insert]; For the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Concord, CA: Cerus Corporation; January 20, 2021.

## WINNING WITH A NOVEL STATISTICAL ANALYSIS IN CT TRIALS: USE OF THE WIN RATIO

*Kevin W. Lobdell, Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC*

*Andrew D. Shaw, Cleveland Clinic, Cleveland, OH*

*Andre Lamy, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada*

>> continued from page 1

1-2 days prior to surgery, could potentially improve clinical outcomes across various organ systems, including the heart, lung, kidneys, liver, and brain, based on preclinical data. A recently completed Phase 2 study met the primary endpoint of a cytoprotective preconditioning biomarker response<sup>1</sup>. Additional predefined endpoints included clinical outcomes, such as ventilator, ICU, and hospital days; 30-day readmission rates; AKI incidence; and MAKE- (major adverse kidney events) assessment. Analysis of these outcomes suggested statistically significant or numerical improvement across most domains.

Multi-organ benefits, even if small, could add to meaningful improvement in overall outcomes (akin to the concept of “the aggregation of marginal gains” by Dave Brailsford)<sup>2</sup>. Quantification of such outcomes requires using a relevant composite endpoint. As such, a post-hoc analysis was performed in the Phase 2 study of RBT-1 using the Finkelstein-Schoenfeld method (win ratio)<sup>2</sup>, wherein clinical outcomes were assessed in a

severity-based hierarchy (death > AKI requiring dialysis > ICU days > 30-day cardiopulmonary readmission). This analysis showed that patients treated with RBT-1 had improved outcomes compared to placebo and formed the basis of RBT-1 receiving a Breakthrough Therapy designation by the US FDA, as well as the agency's agreement on a hierarchical composite endpoint for the upcoming Phase 3 RBT-1 clinical trial.

The win ratio's hierarchical structure, flexibility and statistical power (every placebo patient is compared to every treatment patient) make it an attractive approach for determining efficacy of randomized treatments. Lack of familiarity of the win ratio among clinicians and regulatory entities may have slowed its initial utilization and broad adoption in clinical trial design, however change is afoot.<sup>3</sup> This novel endpoint approach, which allows multi-organ benefits to be examined across continuous and binary variables based upon severity, could form the basis of future clinical trial designs in cardiac surgery.

1. Lamy A et al. A Randomized, Blinded, Multi-Center, Phase 2 Trial of RBT-1 Versus Placebo Evaluating Cytoprotective Biomarkers and Postoperative Outcomes in Patients Undergoing Elective Coronary Artery Bypass Graft and/or Valve Surgery on Cardiopulmonary Bypass. *AATS 2023 Annual Meeting –Late-Breaking Abstract*.

2. Fleming IO, Garratt C, Guha R, et al. Aggregation of Marginal Gains in Cardiac Surgery: Feasibility of a Perioperative Care Bundle for Enhanced Recovery in Cardiac Surgical Patients. *J Cardiothorac Vasc Anesth.* 2016 Jun;30(3):665-70. doi:10.1053/j.jcva.2016.01.017.

3. Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. *Eur Heart J.* 2020;41(46):4391-4399. doi:10.1093/euroheartj/ehaa665

4. Ferreira JP, Jhund PS, Duarte K, et al. Use of the Win Ratio in Cardiovascular Trials. *JACC Heart Fail.* 2020;8(6):441-450. doi:10.1016/j.jchf.2020.02.010

# POST-OPERATIVE ATRIAL FIBRILLATION: CLINICAL IMPLICATIONS, GUIDELINES, AND EMERGING EVIDENCE

Marc W Gerdisch MD

Loyola University Medical Center, Chicago, IL

>> continued from page 1

oral anticoagulation (OAC) has an ESC/EACTS Class IIb recommendation (LOE B) for POAF patients at risk of stroke after cardiac surgery, noting net clinical benefit and patient preference should be considered. This may reflect the mixed published outcomes on the role of OAC in POAF patients regarding stroke prevention versus bleeding risk.

There is emerging evidence on strategies to prophylactically reduce POAF incidence

In summary, the increased morbidity and mortality associated with POAF are well-documented. Research on various prophylactic interventions to prevent POAF continues but underscores the importance of peri-operative rhythm/rate control combined with long-term rhythm monitoring for at-risk patients.

*1. Ahlsson A, Fengsrød E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial*

*Fibrillation after Cardiac Surgery. J Thorac Cardiovasc Surg. 2023.*

*6. Kiankhooy A, Sertic F, Daw M, Eisenberg S, Kiankhooy A, Dunnington G. Non-atriotomy surgical ablation is associated with a reduction of postoperative atrial fibrillation. Ann Thorac Surg Short Rep. 2023;https://www.annalsthoracicsurgeryshortrep.org/article/S2772-9931(23)00303-0/fulltext.*

*7. Ge P, Fu Y, Su Q, et al. Colchicine for prevention of post-operative atrial fibrillation: Meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9:1032116.*

*8. Gaudino M, Sanna T, Ballman KV, et al. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet. 2021;398(10316):2075-2083.*

*9. Chikwe J, Roach A, Emerson D, et al. Left atrial appendage closure during mitral repair in patients without atrial fibrillation. J Thorac Cardiovasc Surg. 2023.*

*10. Gerdisch MW, Garrett HE, Jr, Mumtaz MA, et al. Prophylactic Left Atrial Appendage Exclusion in Cardiac Surgery Patients With Elevated CHA(2)DS(2)-VASc Score: Results of the Randomized ATLAS Trial. Innovations (Phila). 2022;17(6):463-470.*

*11. Gercek M, Borgermann J, Gercek M, Gummert J. Left atrial appendage amputation concomitant*

## RESEARCH ON VARIOUS PROPHYLACTIC INTERVENTIONS TO PREVENT POAF CONTINUES BUT UNDERSCORES THE IMPORTANCE OF PERI-OPERATIVE RHYTHM/RATE CONTROL COMBINED WITH LONG-TERM RHYTHM MONITORING FOR AT-RISK PATIENTS.

at index procedure. Prophylactic radiofrequency ablation of the left atrium has recently been published with evidence of decreased POAF.<sup>5,6</sup> Because substrate is modified, it has the potential to translate into longer term AF reduction. Myocardial inflammation reduction has been explored with colchicine<sup>7</sup> or posterior periocardiotomy<sup>8</sup>, which recently received a 2a (LOE B) ACC recommendation for POAF reduction. Prophylactic exclusion of the left atrial appendage (LAA), the predominant site of thrombus in AF, has been evaluated in feasibility and retrospective studies.<sup>9-11</sup> LeAAPS (NCT05478304) is an ongoing prospective, multi-center, randomized, superiority trial to evaluate the effectiveness of LAAE for the prevention of ischemic stroke or systemic arterial embolism in non-AF cardiac surgery patients who have risk factors for AF and ischemic stroke.

fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg. 2010;37(6):1353-1359.

*2. Lee SH, Kang DR, Uhm JS, et al. New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J. 2014;167(4):593-600 e591.*

*3. Eikelboom R, Sanjanwala R, Le ML, Yamashita MH, Arora RC. Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2021;111(2):544-554.*

*4. Caldonazo T, Kirov H, Rahouma M, et al. Atrial fibrillation after cardiac surgery: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2023;165(1):94-103 e124.*

*5. Willekes CL, Fanning JS, Heiser JC, et al. Randomized Feasibility Trial of Prophylactic Radiofrequency Ablation to Prevent Atrial*



To learn more about our organization, including our board members and upcoming meetings:  
[www.erascardiac.org](http://www.erascardiac.org)





## COACHES CORNER

## ERAS PROGRAM IN THE SPOTLIGHT

## THE I HATE INFECTIONS TEAM (#IHIT)

*Mike Modrow PA-C  
WakeMed Health, Raleigh NC*

Patient-related interventions	<ul style="list-style-type: none"> <li>Preoperative MRSA identification</li> <li>Individualized perioperative antibiotics</li> <li>Antimicrobial dosing strategies</li> <li>Normothermia maintenance</li> </ul>
Environment-related interventions	<ul style="list-style-type: none"> <li>Proper OR ventilation</li> <li>OR professional cleaning</li> <li>Reducing airborne particle counts</li> <li>Decreasing OR foot traffic</li> </ul>
Operative-related interventions	<ul style="list-style-type: none"> <li>Glycemic control</li> <li>Sternal adhesives and medications</li> <li>Rigid sternal plating for high risk patients</li> <li>Use of disposable healthcare equipment</li> <li>Use of CHG dressings over invasive lines</li> </ul>



>> continued from page 1

Environment-related interventions included optimizing operating room ventilation and terminal cleaning, reducing airborne particle counts, and decreasing OR foot traffic.

We even now have an after-discharge care plan in place called Tele Heart Care. This program affords for a minimum of two additional APP touch points, prior to the patient's follow up visit with their surgeon. This allows for real time wound evaluations, to get in front of any developing wound issues, as well as address other post discharge opportunities to adjust medications and evaluate overall post-op well-being etc.

### USE OF THIS BUNDLED INFECTION PREVENTION APPROACH REDUCED THE INCIDENCE TO ZERO FOR THE FIRST 14 MONTHS AFTER IMPLEMENTATION AT OUR INSTITUTION.

Together, these interventions reduced the DSWI incidence from 1.6% pre-intervention to 0% for 14 consecutive months after full bundle implementation. Although the influence of each individual intervention on our DSWI remains unknown, use of this bundled infection prevention approach reduced the incidence to zero for the first 14 months after implementation at our institution. As our executive medical director, Dr. Judson Williams often states- "it is through these marginal gains that our patients benefit the most." The ongoing challenges are continuing educational opportunities, for ever changing staffing, to minimize drift from in place practices. We are doing this through IHIT educational videos, like our ERAS® Virtual Training Center video, and continuing educational in-service opportunities. Of course the above interventions clearly are not all inclusive but rather representative of an organized, multimodal, multidisciplinary approach to achieving ZERO deep sternal wounds. The effort, we believe, MATTERS to achieving optimal enhanced recovery after surgery(ERAS)! Good luck on your journey to ZERO!

1. Abu-Omar Y, Kocher GJ, Bosco P, Barbero C, Waller D, Gudbjartsson T et al. European Association for Cardio-Thoracic Surgery expert consensus statement on the prevention and management of mediastinitis. Eur J Cardiothorac Surg 2017;51:10–29.
2. Eliminating sternal wound infections: Why every cardiac surgery program needs an I hate infections team <https://doi.org/10.1016/j.jtc.2023.03.019>

## IN THE NEWS:



**Busra Cangut, MD is the 2024 recipient of the Richard Engelman Cardiac Enhanced Recovery Fellowship Award.**

## Announcing the 2024 ERAS® Cardiac Fellowship Awardee:

We are proud to announce that **Busra Cangut, MD** is the 2024 recipient of the **Richard Engelman Cardiac Enhanced Recovery Fellowship Award**. This award affords the recipient the opportunity to join the ERAS® Cardiac Executive Board in focused research, collaboration, and presentations at academic meetings. The intent is to provide an enriched experience for the awardee to gain advanced training in perioperative care of cardiac surgical patients. Awardees may also travel to expert institutions for advanced training.

Dr. Busra Cangut completed her medical school at Istanbul-Marmara University School of Medicine and pursued her basic science research year, postdoctoral fellowship, master's degree and general surgery intern year at Mayo Clinic.



**Dr. Richard Engelman**

She is currently working on the development of novel cardiac imaging technologies for specific valve pathologies as well as clinical outcome research at Mount Sinai Hospital/New York. Her multifaceted approach to cardiothoracic surgery, encompassing basic science, clinical, and imaging aspects, reflects her unique and holistic understanding of the field.

Beyond her outstanding research and clinical accomplishments, Dr. Cangut has demonstrated exemplary commitment, dedication, and leadership in her role as the committee chair for Women in Thoracic Surgery (WTS). Her exceptional contributions to the field have been recognized with the prestigious 2023 STSA Carpenter Scholarship, a testament to her unwavering dedication to advancing medical knowledge.



### ERAS® Cardiac Society Executive Board in Lisbon

The ERAS® Cardiac Society Executive Board met in Lisbon this June at the ERAS® World Congress, where they were invited to present a specialty session on innovations in cardiac surgery.

## Introducing the Virtual Training Center

**Amanda Rea, DNP, CRNP, University of Maryland St. Joseph Medical Center, Towson, MD**  
**Alex Gregory, MD, Cumming School of Medicine & Libin Cardiovascular Institute, University of Calgary, Alberta, CA**

The Enhanced Recovery After Surgery (ERAS®) Cardiac Society strives to promote the engagement and adoption of ERAS® protocols for the cardiac surgery patients around the world. Traditionally, this has been accomplished through publications, work groups, and presentations on national and international platform from meetings and conferences hosted by the expert organizations that support the cardiac surgery perioperative continuum.

In October, the ERAS® Cardiac Society launched a new membership for the global enhanced recovery community. One of the benefits of membership is access to educational resources, materials and presentations that have been collated into a platform titled The Virtual Training Center (VTC). The VTC includes experts from all across the world providing recorded presentations on topics of ERAS®. In addition to the presentations, the society developed implementation materials for team members to utilize when developing or expanding an ERAS® program. These items are all customizable for individual institutions and have been developed by leaders whom have implemented and sustained successful ERAS® programs. Examples of the items included are an implementation checklist, a standardized patient education booklet, visual pathways for patients and healthcare teams, a PowerPoint for team education, an ERAS® coordinator job description, and a data tracking spreadsheet. The VTC will continue to evolve by adding content on a regular basis to provide the most up to date information and resources. This entire platform was designed to provide teams and individuals with the tools we wish we had when embarking on this ERAS® adventure. Our goal is to continue perfecting the surgical journey by spreading the word, supporting each other, researching, and providing evidenced based care to improve our patients' outcomes.

Scan the QR code to sign up for the ERAS® Cardiac membership.



## RECENT ERAS® CARDIAC PUBLICATIONS:

>> Click titles for weblinks

- 1. The Association Between Enhanced Recovery After Cardiac Surgery-Guided Analgesics and Postoperative Delirium.** Jelly CA, Clifton JC, Billings FT 4th, Hernandez A, Schaffer AJ, Shotwell ME, Freundlich RE. J Cardiothorac Vasc Anesth. 2023 May;37(5):707-714.
- 2. Update on minimally invasive cardiac surgery and enhanced recovery after surgery.** Salenger R, Lobdell K, Grant MC. Curr Opin Anaesthesiol. 2023 Oct 12. online
- 3. Patient and caregiver preferences and prioritized outcomes for cardiac surgery: A scoping review and consultation workshop.** Oravec N, Arora RC, Bjorklund B, Gregora A, Monnin C, Dave MG, Duhamel TA, Kent DE, Schultz ASH, Chudyk AM. J Thorac Cardiovasc Surg. 2023 Aug;166(2):598-609.e7.
- 4. Enhanced Recovery After Cardiac Surgery: A Social Determinants of Health Lens.** Khusid E, Lui B, Hoyler M, Rozental O, White RS. J Cardiothorac Vasc Anesth. 2023 Oct;37(10):1855-1858.
- 5. Adult Cardiac Surgery-Associated Acute Kidney Injury: Joint Consensus Report.** Brown JK, Shaw AD, Mythen MG, Guzzi L, Reddy VS, Crisafi C, Engelman DT; PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Workgroup. J Cardiothorac Vasc Anesth. 2023 Sep;37(9):1579-1590.
- 6. Benefits of Prehabilitation before Complex Aortic Surgery.** Mesnard T, Dubosq M, Pruvot L, Azzaoui R, Patterson BO, Sobocinski J. J Clin Med. 2023 May 26;12(11):3691.
- 7. Cardiac Rehabilitation and Its Role in Enhanced Recovery After Surgery.** Stoppe C, Engelman DT. Ann Thorac Surg. 2023 Nov;116(5):1105-1106.
- 9. Outcomes Related to Cardiac Enhanced Recovery After Surgery Protocol.** Pollock KM, Ambroziak R, Mullen C, King L, Barsa A. J Cardiothorac Vasc Anesth. 2023 Aug;37(8):1403-1409.
- 10. Determination of Knowledge and Attitudes of Cardiac Surgery Nurses Regarding the Enhanced Recovery After Surgery Protocol.** Doruker NC, Oden TN, Korkmaz FD. J Perianesth Nurs. 2023 Oct;38(5):710-716.
- 11. The standard of care: 'standardized care'.** Salenger R, Engelman DT. Eur J Cardiothorac Surg. 2023 May 2;63(5):ezad188.
- 12. Enhanced recovery after surgery: a narrative review on patient blood management recommendations.** Mendez E, Puig G, Barquero M, Leon A, Bellafont J, Colomina MJ. Minerva Anestesiol. 2023 Oct;89(10):906-913.
- 13. Role of Cardiac Anesthesiologists in Intraoperative Enhanced Recovery After Cardiac Surgery (ERACS) Protocol: A Retrospective Single-Center Study Analyzing Preliminary Results of a Yearlong ERACS Protocol Implementation.** Mondal S, Bergbower EAS, Cheung E, Grewal AS, Ghoreishi M, Hollander KN, Anders MG, Taylor BS, Tanaka KA. J Cardiothorac Vasc Anesth. 2023 Dec;37(12):2450-2460.
- 14. Enhanced Recovery After Surgery in Cardiac Surgery: Imploring Investigation.** Yoo J, Sabatino ME, Yang NK, Soliman FK, Olds N, Zhang Y, Lee LY. Ann Thorac Surg. 2023 Jun;115(6):1559-1560.
- 15. Knowledge, Implementation, and Perception of Enhanced Recovery After Surgery Amongst Surgeons in Pakistan: A Survey Analysis.** Ahmad H, Shehdio W, Tanoli O, Deckelbaum D, Pasha T. Cureus. 2023 Sep 26;15(9):e46030. PMID: 37900487 **Free PMC article.**
- 16. Pain management and opioid stewardship in adult cardiac surgery: Joint consensus report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society.** Grant MC, Chappell D, Gan TJ, Manning MW, Miller TE, Brodt JL; PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society Workgroup. J Thorac Cardiovasc Surg. 2023 Dec;166(6):1695-1706.e2.
- 17. Efficacy of erector spinae plane block for minimally invasive mitral valve surgery: Results of a double-blind, prospective randomized placebo-controlled trial.** Hoogma DF, Van den Eynde R, Al Tmimi L, Verbrugghe P, Tournoy J, Fieuws S, Coppens S, Rex S. J Clin Anesth. 2023 Jun;86:111072.
- 18. Introducing Cardiac Enhanced Recovery After Surgery best practices in Saskatchewan.** O'Brien J, Barbour-Tuck E, Xia L, Campbell K, Reimche E, Valiani S, Pikaluk R, Clunie M. Can J Anaesth. 2023 Aug;70(8):1409-1410.
- 19. Erector spinae plane block for postoperative analgesia in robotically-assisted coronary artery bypass surgery: Results of a randomized placebo-controlled trial.** Hoogma DF, Van den Eynde R, Oosterlinck W, Al Tmimi L, Verbrugghe P, Tournoy J, Fieuws S, Coppens S, Rex S. J Clin Anesth. 2023 Aug;87:111088.
- 20. Results following implementation of a cardiac surgery ERAS protocol.** Obafemi T, Mullis D, Bajaj S, Krishna P, Boyd J. PLoS One. 2023 Jul 14;18(7):e0277868.
- 21. Comparison of Transversus Thoracis Muscle Plane Block and Pecto-Intercostal Fascial Plane Block for enhanced recovery after pediatric open-heart surgery.** Elbardan IM, Shehab AS, Mabrouk IM. Anaesth Crit Care Pain Med. 2023 Aug;42(4):101230.
- 22. State of the art: Proceedings of the American Association for Thoracic Surgery Enhanced Recovery After Cardiac Surgery Summit.** Chatterjee S, Arora RC, Crisafi C, Crotwell S, Gerdisch MW, Katz NM, Lobdell KW, Morton-Bailey V, Pirris JP, Reddy VS, Salenger R, Varelmann D, Engelman DT. JTCVS Open. 2023 Apr 15;14:205-213.
- 23. Pro: Regional Anesthesia for Cardiac Surgery With Sternotomy.** Rubio G, Ibekwe SO, Anton J, Tolpin D. J Cardiothorac Vasc Anesth. 2023 Jun;37(6):1042-1045.

## PUBLICATIONS (CONT'D):

>> Click titles for weblinks

[24. An enhanced recovery programme significantly improves postoperative outcomes after surgical aortic valve replacement.](#)

Giger A, Schneider C, Marguerite S, Ramlugun D, Maechel AL, Collange O, Mertes PM, Mazzucotelli JP, Kindo M. Eur J Cardiothorac Surg. 2023 May 2;63(5):ezad125.

[25. Perioperative Implementation of Low-Dose Pregabalin in an Enhanced Recovery After Cardiac Surgery Protocol: A Pre-Post Observational Study.](#)

Patel A, Shah A, Apigo A, Lin HM, Ouyang Y, Huang K, Friedman S, Yimen M, Puskas JD, Bhatt HV. J Cardiothorac Vasc Anesth. 2023 Oct 3:S1053-0770(23)00830-3.

[26. Comparative Efficacy of Adjuvant Nonopioid Analgesia in Adult Cardiac Surgical Patients: A Network Meta-Analysis.](#)

Heybati K, Zhou F, Lynn MJ, Deng J, Ali S, Hou W, Heybati S, Tzanis K, Krever M, Mughal R, Ramakrishna H. J Cardiothorac Vasc Anesth. 2023 Jul;37(7):1169-1178.

[27. Eliminating sternal wound infections: Why every cardiac surgery program needs an I hate infections team.](#)

Downing M, Modrow M, Thompson-Brazill KA, Ledford JE, Harr CD, Williams JB. JTCVS Tech. 2023 Apr 14;19:93-103.

[28. Parasternal intercostal plane block catheters for cardiac surgery: a retrospective, propensity weighted, cohort study.](#)

Francis L, Condrey J, Wolla C, Kelly T, Wolf B, McFadden R, Brown A, Zeigler S, Wilson SH. Pain Manag. 2023 Jul;13(7):405-414.

[29. Enhanced recovery after surgery program for patients undergoing isolated elective coronary artery bypass surgery improves postoperative outcomes.](#)

Schneider C, Marguerite S, Ramlugun D, Saadé S, Maechel AL, Oulehri W, Collange O, Mertes PM, Mazzucotelli JP, Kindo M. J Thorac Cardiovasc Surg. 2023 Aug 21:S0022-5223(23)00730-4.

[30. The Effect of Visits by Operating Room Nurses Before Cardiac Surgery on Anxiety and Pain Management.](#)

Arpag N, Öztekin SD. J Perianesth Nurs. 2023 Dec;38(6):892-900.

[31. ERAS Cardiac society turnkey order set for patient blood management: Proceedings from the AATS ERAS Conclave 2023.](#)

Salenger R, Hirji S, Rea A, Cangut B, Morton-Bailey V, Gregory AJ, Arora RC, Grant MC, Raphael J, Engelma DT; ERAS Cardiac Working Group. J Thorac Cardiovasc Surg. 2023 Oct 20:S0022-5223(23)00991-1.

[32. Deep Parasternal Intercostal Plane Block for Postoperative Analgesia After Sternotomy for Cardiac Surgery-A Retrospective Cohort Study.](#)

Skojec AJ, Christensen JM, Yalamuri SM, Smith MM, Arghami A, LeMahieu AM, Schroeder DR, Mauermann WJ, Nuttall GA, Ritter MJ. J Cardiothorac Vasc Anesth. 2023 Oct 4:S1053-0770(23)00829-7.

[33. Cardiac ERAS in the Community: Real-World Results for Real Patients.](#)

Salenger R, Rea A, Barr LF. Ann Thorac Surg. 2023 Jun;115(6):1560-1561.

## UPCOMING MEETINGS:

>> Click on icons for weblinks



Society of Critical Care Medicine  
Critical Care Congress  
*San Francisco, CA*  
*January 21-24, 2024*



Society of Cardiovascular  
Anesthesiologists 46th Annual  
Meeting  
*Toronto, Canada*  
*April 27-30, 2024*



European Association for  
Cardio-Thoracic Surgery 38th  
Annual Meeting  
*Lisbon, Portugal*  
*October 9-12, 2024*



Society of Thoracic Surgeons 60th  
Annual Meeting  
*San Antonio, TX*  
*January 27-29, 2024*



Evidence Based Perioperative  
Medicine World congress 2024  
*London, England*  
*July 2-4, 2024*



Society of Thoracic Surgeons  
Perioperative Medicine and  
Critical Care Meeting  
*Philadelphia, PA*  
*October 24-30, 2024*



American Association for Thoracic  
Surgery 104th Annual Meeting  
*Toronto, Canada,*  
*April 27-30, 2024*



10th ERAS World Congress  
*Malaga, Spain*  
*September 18-20, 2024*

## ERAS® Cardiac Society MISSION

***The mission of the ERAS® Cardiac Society is to optimize perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best practices worldwide.***

### Who We Are

The ERAS® Cardiac Society is an international non-profit organization comprised of experts from around the world, including participation from all members of the healthcare team. Led by an executive board, an advisory board, and a pool of subject matter experts, our members strive to implement enhanced recovery principles at their local institutions while advancing improved patient care internationally through collaboration, education, and dissemination of up-to-date knowledge regarding optimal perioperative care.

### ERAS® Society

The ERAS® Society is an international organization with enhanced recovery guidelines for several surgical sub-specialties. Beginning as the ERAS® Study Group in 2001, team leaders Professor Ken Fearon (University of Edinburgh) and Professor Olle Ljungqvist (Karolinska Institutet) spearheaded the developments made in multimodal surgical care. The ERAS® Study Group soon discovered that there were a variety of local traditions in practice, as well as an inconsistent application of evidence-based best practices. This prompted the group to examine the process of change from tradition to best-practice. Since its inception, the ERAS® Society has expanded to include several subspecialties, emphasized the benefits of standardized best-practices across the continuum of the perioperative period, highlighted the importance of data-driven self-evaluation, and promoted the improvement of patient care.

### Our Organizational Structure

Our ERAS® Cardiac Society is made up of experts from around the world, including participation from all members of the healthcare team. Our members strive to implement enhanced recovery principals at their local institutions while advancing improved patient care internationally through collaboration, education, and dissemination of up-to-date knowledge regarding optimal perioperative care. Our organization is divided into an Executive Board, Advisory Board, and a pool of Subject Matter Experts.



Kim Pehle  
Administrator,  
ERAS® Cardiac Society  
[k.pehle@erascardiac.org](mailto:k.pehle@erascardiac.org)  
612.760.1413

Donna Frankel  
Office Manager,  
ERAS® Cardiac Society  
[donnaerasc@gmail.com](mailto:donnaerasc@gmail.com)

To learn more about our organization,  
including our board members and  
upcoming meetings:  
[www.erascardiac.org](http://www.erascardiac.org)



## ERAS® Cardiac Society SPONSORS



Corporate financial support will be used to promote the mission of the ERAS® Cardiac Society. We are committed to standardizing best practice surrounding the preoperative and perioperative care of cardiac surgical patients through expert consensus, review of the literature and open communication. This unrestricted support does not represent the ERAS® Cardiac Society's support or agreement to promote any pharmaceutical, device, or technology related to the sponsors.

For more information and to become a sponsor please contact:

Administrator Kim Pehle at [k.pehle@erascardiac.org](mailto:k.pehle@erascardiac.org)

## EXECUTIVE BOARD

**Daniel Engelman, MD**  
**President**  
Cardiac Surgeon  
Baystate Medical Center  
USA

**Michael Grant, MD**  
**Vice President**  
Cardiac Anesthesia and Critical Care  
Medicine Intensivist  
Johns Hopkins  
USA

**Alex Gregory, MD**  
**Secretary**  
Cardiac Anesthesia Intensivist  
University of Calgary  
Canada

**Kevin Lobdell, MD**  
**Treasurer**  
Cardiac Surgeon Intensivist  
Sanger Heart & Vascular Institute,  
Charlotte, NC  
USA

**Rakesh Arora, MD, PhD**  
Cardiac Surgeon Intensivist  
University Hospitals (UH)  
Harrington Heart & Vascular Institute  
USA

**Subhasis Chatterjee, MD**  
Cardiac Surgeon Intensivist  
Baylor College of Medicine  
USA

**Cheryl Crisafi MSN, RN, CNL**  
Nurse Coordinator ERAS® Cardiac  
Society  
Baystate Medical Center  
USA

**Marjan Jahangiri, MBBS, MS, FRCS,**  
**FRCS (CTh)**  
Cardiac Surgeon  
St. Georges University of London UK

**Vicki Morton-Bailey, DNP, MSN,**  
**AGNP-BC**  
Director of Clinical and Quality  
Outcomes  
Providence Anesthesiology Associates  
USA

**V. Seenu Reddy, MD, MBA, FACS**  
Cardiac Surgeon  
Centennial Heart & Vascular Center,  
USA

## ADVISORY BOARD

**Keith Allen, MD**  
St. Luke's Mid America Heart  
Institute  
USA

**Ed Boyle, MD**  
St. Charles Medical Center  
USA

**Jessica Brodt, MD**  
Anesthesiology, Palo Alto, CA  
USA

**Shannon Crotwell RN, BSN, CCRN**  
Sanger Heart & Vascular Institute,  
Charlotte, NC  
USA

**Andre Denault, MD, PhD, FRCPC,**  
**FASE, FCCS**  
Montreal Heart Institute and  
Centre Hospitalier de l'Université de  
Montréal  
Canada

**Joerg Ender, MD**  
Heart Center  
Leipzi  
Germany

**Jill Engel, DNP, FNP, ACNP, NEA-BC,**  
**FAANP**  
Duke University Medical Center  
USA

**Nick Fletcher, MBBS, FRCA, FFICM**  
St Georges Hospital NHS Trust,  
London  
UK

**Marc Gerdisch, MD, FACS, FACC**  
Franciscan Health Heart Center  
USA

**Serdar Gunaydin, MD, PhD**  
Cardiovascular Surgery  
University of Health Sciences,  
Turkey

**Sameer Hirji, MD, MPH**  
Harvard Medical School, USA

**Karim Jabr, CCP, LP CSSBB**  
Medical Center-Navient Health,  
USA

**Lian Kah**  
Assoc Professor  
Yong Loo Lin School of Medicine,  
Anesthesia  
Singapore

**Ali Khoyneshad, MD, PhD, FACS,**  
**FHRS**  
Memorial Care Long Beach  
Medical Center  
USA

**Yoan Lamarche- MD MSc FRSCS**  
Montreal Heart Institute, Université  
de Montréal  
Canada

**Gina McConnell, BSN, RN, CCRN**  
ERAS® Coordinator at WakeMed  
Health  
USA

**Gregg Nelson, MD, PhD**  
University of Calgary  
Canada

**Tom Nguyen, MD**  
Memorial Hermann Heart &  
Vascular Institute  
USA

**Louis Perrault, MD, PhD, FRCSC,**  
**FACS, FECS**  
Montreal Heart Institute, Université  
de Montréal  
Canada

**John Pirris, MD**  
University of Florida Health  
USA

**Amanda Rea, DNP, CRNP**  
University of Maryland St Joseph  
Medical Center  
USA

**Eric Roseli, MD FACS**  
Cleveland Clinic  
USA

**Michael Sander, MD**  
Uniklinikum Giessen und  
Marburg  
Germany

**Michael Scott**  
Anesthesia and Critical Care  
University of Pennsylvania,  
Philadelphia  
USA

**Andrew Shaw, MD**  
University of Alberta  
Canada

**Christian Stoppe, MD, FAHA,**  
**RWTH**  
Aachen University  
Germany

**Judson Williams, MD, MHS**  
WakeMed Heart & Vascular  
USA

**Alex Zarbock, MD**  
University Hospital Münster,  
Germany



To learn more about our organization, including our board  
members and upcoming meetings:  
[www.erascardiac.org](http://www.erascardiac.org)

